LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
ZCMD
Zhongchao Inc.
There isn't enough reported data to score ZCMD yet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ZCMD Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
ZCMD's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ZCMD PE Valuation
ZCMD has no meaningful PE right now: it lost money over the past year.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
ZCMD Forward outlook
There aren't enough analyst estimates for ZCMD to show an outlook.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over ZCMD in the latest year-over-year earnings comparison.
ZCMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2024 | -$178.56 | +$6,300.19 |
| Q2 2024 | -$3,755.71 | +$604.13 |
| Q4 2023 | -$6,478.75 | -$4,797.31 |
| Q2 2023 | -$4,359.84 | -$3,904.65 |
| Q4 2022 | -$1,681.44 | -1301% |
| Q4 2021 | $140.01 | -95% |
| Q4 2020 | $2,723.04 | -2.1% |
ZCMD lost $178.56 per share over the past year, a smaller loss than the year before.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over ZCMD in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY's operating margin was 34% last quarter, down 6.6 points from the same quarter a year ago.
ZCMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $5.8M | -23% |
| Q2 2025 | $5.6M | -33% |
| Q4 2024 | $7.5M | -17% |
| Q2 2024 | $8.3M | -20% |
| Q4 2023 | $9.1M | +32% |
| Q2 2023 | $10.4M | +42% |
| Q4 2022 | $6.9M | -11% |
| Q2 2022 | $7.3M | -15% |
ZCMD's revenue has slid since its 2020 peak: $6M last quarter, down 36% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -92% | -12 points |
| Q2 2025 | -16% | +42 points |
| Q4 2024 | -3.9% | +39 points |
| Q2 2024 | -0.6% | -5.8 points |
| Q4 2023 | -80% | -65 points |
| Q2 2023 | -58% | -70 points |
| Q4 2022 | -43% | -70 points |
| Q2 2022 | 5.2% | -24 points |
ZCMD's operating margin was −92% last quarter, down 12 points from the same quarter a year ago, near the bottom of its range since 2019.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
ZCMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2024 | -$3.2M | -399% |
| Q2 2024 | -$1.3M | +$579.7K |
| Q4 2023 | $1.1M | +$2.5M |
| Q2 2023 | -$1.9M | -$1M |
| Q4 2022 | -$1.5M | -210% |
| Q2 2022 | -$821.9K | -$561.4K |
| Q4 2021 | $1.3M | +$2.5M |
| Q4 2020 | -$1.2M | -1360% |
ZCMD has burned cash in most quarters: −$5M over the past year, against −$1M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over ZCMD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ZCMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.3% | +22 shares |
| 1 year | +1.5% | +26 shares |
ZCMD has 1,772 diluted shares, up 1.5% from a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ZCMD Net Leverage
ZCMD's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ZCMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 23.0 | Oversold |
| Stochastic | 3.0 | Oversold |
ZCMD's weekly RSI is 23 (oversold) and its Stochastic is 3 (oversold).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ZCMD PE vs Healthcare Sector
| Metric | ZCMD | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ZCMD has no meaningful PE right now: it lost money over the past year.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over ZCMD on trend strength, trading above more of its moving averages.
ZCMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.35 | 31% below |
| 20 week MA | $1.90 | 51% below |
| 50 week MA | $251.7 | 100% below |
| 100 week MA | $981.6 | 100% below |
| 200 week MA | $5,187.8 | 100% below |
ZCMD is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over ZCMD on returns for 2026, with the stronger performance.
ZCMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $58,180.8 | $26,188.8 | -55% |
| 2021 | $26,188.8 | $27,081.6 | +3.4% |
| 2022 | $27,081.6 | $17,260.8 | -36% |
| 2023 | $17,260.8 | $5,224.4 | -70% |
| 2024 | $5,224.4 | $2,455.2 | -53% |
| 2025 | $2,455.2 | $757.4 | -69% |
| 2026 YTD | $757.4 | $0.93 | -100% |
ZCMD has finished four years in a row lower, and it's down 100% so far in 2026.